

# Index

---

- Abbott III, T.A. 47  
Abel-Smith, B. 184  
Abril Committee 222  
acute viral respiratory infections 167  
adjustment factor 48  
administrative costs 39  
advertising 42, 43, 88  
    in Spain 173  
age 140,142, 178  
ageing population 192  
agency relationship 48, 116  
AIDS treatment 97, 127, 156, 191  
alternatives, cheaper 106  
Alzheimer's disease 162  
American experience of co-payment  
    138–41  
Amix brand 61  
amoxicilin 61  
anatomico-therapeutic subgroups 64  
Andreu, J. 209  
angiotensin 113  
Anitua, C. 242  
anti-arrhythmic drugs 64  
anti-asthmatics 191  
antibiotic treatment 136, 167  
anti-coagulants 64  
antidepressants 192  
anti-hypertensive drugs 64, 87, 113, 173  
anti-infective drugs 52  
anti-psychotics 192  
anti-retroviral drugs 127  
Antoñanzas, F. 242  
Antúñez, F. 185  
approval of pharmaceuticals 146  
Argentina 220, 221  
Aristides, M. 166  
Arnés, H. 224, 233, 235, 239  
Arranz, Leopoldo 210  
Arrow, K.J. 21, 33  
asthma 136, 168  
asymmetry of information 135  
Audit Commission UK 178  
Ausió, J. 185, 239  
Australia 41, 51, 105 113, 151, 161, 180  
Austria 8, 41, 137  
authorization process 79, 80, 82  
authorized prices 207  
Averch-Johnson effect 45  
bacterial resistance 167  
Badia Llach x, 17, 145–65, 242  
Balance, R. 99  
Barcelona University 15, 16, 82–3  
barriers to market entry 89  
Bartels-Petersen, J. 186  
Basic Health Zone 204  
Basque Country 229  
behaviour-altering 170  
Belgium 8, 41, 103, 137, 178, 195  
Bercovitz, A. 217, 231, 239  
Bernai-Delgado, E. 186  
Berndt, E.R. 58, 208, 209  
biochips 33  
bioequivalence 70  
biotechnology 26, 33, 220  
blood agents 199  
Bogner, W. 99  
Borrell Arqué, J.R. 59–83, 231, 233,  
    238, 239  
brand name drugs 38, 53, 76, 79, 86–90,  
    113, 117–18, 26–7  
Breyer, S. 33  
British Columbia 105, 108, 113  
British drug consumption 218  
British National Formulary in England 63  
British pharmaceutical expenditure 200  
British system of budgeting 179  
budgets 11,141, 174, 177–9, 184  
Bulgaria 1  
Burstall, M.L. 57  
Cabañas Sáenz, M. 18, 210–30  
Cabiedes Miragaya, L. 18, 167–85, 209,  
    230–39  
Puig-Junoy - 9781845424664

- Callejón, M. 223, 232, 239  
 Canada 51, 53, 105, 108, 151, 161  
 Canton, E. 141, 144  
 capital 43, 45, 46  
 capsules 63  
 Carballeira, R. 220, 232, 240  
 cardiovascular products 64, 117, 199  
 care, cost of 6  
 career development 184  
 Carlos III University, Madrid 18, 212  
 Casado, A. 240  
 Castellón, E. 185  
 Catalonia 204, 229  
 catastrophic diseases 178  
 Caves, R.E. 116, 123  
 centralization 216  
 cephalosporin submarket in USA 38  
 Chaix-Couturier, C. 186  
 Chaqués, Bonafont L. 216, 231, 238  
 charge, additional 88  
 chemical  
   entities 63, 72, 74,  
   equivalence 151  
   preparation 114  
   substances, new 70  
 chronic  
   disease 133, 136, 177  
   obstructive pulmonary disease  
     (COPD) 162  
   processes 137  
 chronically ill people 141, 142  
 citizens' health 33  
 clamoxyl 61  
 clinical  
   management 205  
   practice 167, 177  
   professional standards 168, 169, 174  
   trials 89  
 Cockburn, I. 34  
 co-insurance rate 125  
 commercial  
   brand names 61, 70  
   interests of drug companies 212–13  
   promotion 42, 88  
   technology 28  
 Commission of the European  
   Communities 100  
 companies and clinical trials 173  
 competition 24, 33, 45, 49, 56, 97  
   in pharmaceutical markets 59–83  
     restriction 89–91  
   complementary examinations 182  
   composition of drug 113  
   Conejos, J. 240  
   consensus 180  
   consultation 168  
   consumer  
     choice 97  
     price index (CPI) 3, 137, 219, 220  
     sovereignty 85, 110  
     surplus 23, 24, 27, 31, 37, 95, 96,  
       161  
   consumers 26, 52, 88  
   consumption 50, 105, 118, 119, 149  
   drop 133, 134  
   effects of price regulation on 50–51  
   levels 141  
   of pharmaceuticals 125, 206  
   contagion 156, 163  
   contraceptives 193  
   control systems 50  
   co-payment 124, 125, 171, 219  
     American experience 38–41  
     Italian system 156  
     microeconomic aspects 127–30  
     regulation 137–8, 222  
     in Spain 3  
   copyright 173  
   Correa, C. 99, 215  
   Costas Comesaña, A. 16, 59–83  
   Costas, E. 240  
   cost-benefit analysis (CBA) 145, 158,  
     161  
   cost-benefit ratio 152, 155  
   cost-cutting innovations 47  
   cost-effectiveness 11, 18, 158  
   cost-effectiveness analysis (CEA) 145,  
     181  
   costs 43, 45, 48, 112, 118, 141  
     average 149  
     fixed and sunk 44, 117–18  
     marginal 156  
     sharing 8, 90, 125  
   cost-utility analysis (CUA) 145, 158  
   Cots, F. 242  
   creams 63  
   cross-subsidies 46  
   Cruz-Roche, I. 213, 219, 228, 231–5  
   Cuban researchers 24  
   Culyer, A.P. 166  
   Junoy - 9781845424664

- Cunillera, R. 186  
 cytostatic 199  
 Czech Republic 3
- Danzon, P.M. 57–9, 83, 99, 119–23, 144, 231
- Darbà Coll, J. 16, 84–99, 217, 231, 238, 239
- death 145
- decentralization 184
- defence sector 32
- de Miguel, J. 233
- demand  
   factors 89–91, 218  
   for pharmaceuticals 134  
   functions 129  
   side 117, 169, 204–205
- demographic change 191
- Denmark 44, 97, 113, 137, 181, 195  
   insurer expenditure 119  
   reference pricing (RP) 105, 106
- Department of Health 165, 202
- depression, drugs against 193
- deregulation of pharmaceutical prices 51–6
- developed countries 14, 99
- developing countries 14, 29, 97, 215
- De Vos, C.M. 122
- diabetes 136
- diagnosis 167
- diagnostic  
   agents 199  
   health provision 191  
   value 208
- Dickson, M. 122
- Dimasi, J. 34
- direct-payment prescription 3
- disability 192
- disease 145, 159  
   low-prevalence 32  
   neglected 99  
   new 192
- dispensing of drugs 205
- doctoral theses 212
- doctors 168  
   in health care centres 86  
   information and training 222  
   prescribing behaviour 48, 92, 112, 116, 124, 173  
   salaries 179, 191
- domestic industries 47, 93
- dosage prescribed 64, 136
- drugs 11, 16, 32, 37, 43, 119, 148, 157–8  
   cheap 52, 108, 119, 156, 226  
   consumption 2, 90, 197, 198, 200, 220  
   low 138  
   co-payment 141  
   against depression 193  
   expenditure 135, 189  
   multinational 96  
   old and new 33, 218  
   over-the-counter (OTC) 86  
   patents 87, 114–15, 214  
   prices 18, 79, 82, 97, 105, 142, 171, 224  
   regulation 39–41, 49, 92, 148, 150  
   indexes 219  
   safety 147–8  
   technology 136
- Drummond, M. 122, 165
- dynamic pricing 217
- Eatwell, J. 100
- economic  
   criteria 89  
   evaluation 17, 89, 146, 151, 161  
   and pharmaceutical policy 145–65  
   growth 21  
   studies, Spain 210–30  
   units 92
- education campaigns 189, 181
- elderly people 141, 142
- electricity 208
- employed people 92, 126
- England 16, 66, 70, 178
- English public health sector 81
- entry regulations in UK 80
- enzyme inhibitors 113
- equity 94–7, 98, 114, 124, 142
- equivalence criterion 108, 113–14
- Esteve, J. 220, 232, 240
- Europe 8, 35, 44, 50  
   pharmaceuticals 59, 201
- European Union 60, 97, 169, 189–90, 216  
   countries 51  
   data 139  
   drug policy 214

- European Union (*cont.*):  
 evaluation 217  
 experience of co-payment 138–41  
 on patents 33  
 and pricing 39–40, 96  
 exchange rate fluctuations 93  
 exclusion of drugs 92  
 expenditure 105, 118  
 control policies 217  
 increase 145  
 exports, promotion in UK 79  
 externalities 84
- face-to-face  
 educational sessions 180  
 interviews 180
- family firms 214
- Farma II Plan 221
- Farmaindustria 15, 42, 83, 202, 213, 214, 215
- Fattore, G. 122
- Federal Trade Commission, US 62
- feedback systems 180
- Feldman, R. 143
- Feldstein, M. 131, 143
- Fernández, M.D. 240
- Fernández, P. 236, 242
- Fernández Cano, P. 220, 232
- Ferrandiz, F. 240
- finance burden 132–4
- financial  
 decisions 163–5  
 and non-financial incentives 182  
 risk 179
- financing  
 collective 85  
 mechanisms, public 18, 104, 106  
 of products 146  
 selective in Spain 227–8
- Finland 8, 41, 88, 137, 195
- Fisher, S. 57, 144
- Foguet, R. 240
- Folland, S 143
- Food and Drug Administration (FDA) 157
- formularies 181
- France 40, 41, 51, 97, 151, 178, 195  
 insurance 190
- Franco regime 216
- Frank, R.G. 53, 58, 117, 123, 225, 233
- Franzi, A. 242  
 fraud 142, 171, 173, 183  
 freedom of prices 53, 108, 151  
 Freemantle, N. 143  
 free market 84, 98, 125  
 free-riding 92  
 Freire, J.M. 236  
 fundholdings 179
- Gambardella, A. 58
- Garattini, L. 58
- García, C. 242
- García, M. 236
- García-Fontes, W. 228, 236  
 gastrointestinal system 64
- General Agreement on Tariffs and Trade (GATT) 28, 29, 92
- General Law on Social Security 214
- general practitioner *see* GP
- generics 38, 59, 86, 157, 194, 207  
 competition 16, 53, 65–76, 98  
 drug market 45, 61, 64, 104, 106, 204, 215  
 name 63, 65, 70, 90  
 products 74, 141, 179  
 promotion 88  
 and reference pricing 117, 225–6  
 in USA 5
- genetics, field of 26, 33, 206, 221
- geriatric centres 135
- German pharmaceutical expenditure 200
- Germany 137, 178–80, 195, 222  
 free pricing 41, 44  
 higher prices 40, 51  
 insurance 119, 190  
 reference pricing 105–106, 114, 143
- Gervás, J. 184
- Geursen, R. 83
- Gilbert, R. 26, 33
- Gisbert, R. 229, 234, 236
- Giuliani, G. 123
- Glennester, H. 185
- Glennie, J. 166
- globalization 91, 96, 99, 216
- Gómez, M.E. 185, 186
- González López-Valcárcel, B. 17, 124–43
- González Pérez, R. 18, 210–30
- government intervention 32, 92, 93
- GP fundholder scheme 177, 178, 248, 249

- Grabowski, H.G. 33, 99, 166  
 Granada Francisca Villalba Pérez  
     University 228  
 Granda, E. 240  
 grant system 29, 30  
 Greece 3, 8, 41, 137  
     prices 51  
 Green, D.G. 57  
 Green Paper on Patents 33  
 Griffin, J.P. 83  
 Gross Domestic Product 98, 192, 195,  
     208,  
 group practices 180  
 Güell, R.C. 27, 31, 34  
 Guerra, F. 243  
  
 Hatch-Waxman Act, USA 222  
 health  
     authorities 11, 15, 18, 146  
         Spain 120  
     benefit 145, 160  
     care 124, 128, 141, 189–93, 214  
         and pharmaceuticals in Europe 107  
         environment, Spain 120  
         insurance market 125, 129, 141  
         policy 3, 50, 91, 105, 127, 183  
         process 168, 184  
         professionals 174, 179, 180, 181  
         spending 2–10, 121, 152  
         status 140, 142, 164  
         status of population 140, 201  
         status of system 8, 36, 39  
 Health and Pharmaceuticals Social  
     Studies Seminar 212  
 Health Economics Association (EU)  
     211, 212, 213  
 Health Maintenance Organizations, US  
     135  
 Health Outcomes Research Unit 17  
 Hellerstein, J.K. 123  
 Herfindahl-Hirschman index 61  
 Hernández, J.M. 223, 240  
 high-cost treatments 178  
 high-income households 132  
 high-price countries 93  
 Hill, S. 166  
 Hillman, A. 140, 143  
 Hitiris, T. 139, 144  
 homogeneous drugs 85  
 hormones 199  
  
 Horowitz, A. 26, 33  
 hospital  
     admission 135  
     drugs 86  
     pharmacy 181  
     services 177  
     solutions 199  
 Hotelling 228  
 human genome 27  
 Hungary 1, 2, 3, 41  
 hypertension 136, 162  
 hypolipidaemic drugs 173  
  
 iatrogenia 135–6  
 Ibern Regàs, P. 14, 21–33, 209, 240, 243  
 Iceland 9, 180  
 Ignacio Arango 215  
 Ignacio Cruz-Roche 227  
 illness 126, 127, 136  
 impotence 193  
 incentives 16, 18, 45  
     absence of 89  
     for innovation 21–33, 115  
     institutional 141  
     prescribing 182  
     professional 25  
 income 131, 140, 142  
 industrial  
     economics 212, 213, 221  
     policy 79, 183, 208, 224  
     secrecy 25  
 infections 136  
 infectious diseases 156  
 inflation index 7, 49  
 information 11, 18, 84, 181  
     lack of 116, 135  
 ingredients, active 63, 65, 67, 79, 121,  
     132, 181  
 injectables 63  
 innovation 14, 23, 25, 28, 32, 80, 216,  
     221  
     promotion in UK 79  
 innovative drugs 86, 87, 93, 96, 98  
 INSALUD 83  
 institutional context 169–74  
 Instituto Nacional de Estadística (INE)  
     83  
 insurance 37, 125, 139, 146  
     companies 160–61  
     coverage of pharmaceuticals 145, 152, 160, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000

- insurance (*cont.*):  
  markets 125–7, 138  
  premium 125, 126  
  tradition of 190  
insurers 132–4  
intellectual property 28, 97, 98  
Intercontinental Medical Systems (IMS)  
  45, 212  
interests, conflict of 183  
international  
  experience in pricing 109, 137–41,  
  150–51  
  prices 44, 50, 97, 98, 206  
  research and development (R & D)  
  99  
  trade 193, 221  
International Conference of the  
  European Network on Industrial  
  Policy 83  
International Federation of  
  Pharmaceutical Manufacturers 9  
International Health Economics 226  
International Non-Proprietary Name  
  (INN) 86  
inventions, legal protection 22  
investment 28  
  research and development (R & D)  
  91, 98  
Ireland 9, 137, 178, 180, 182  
Italy 9, 41, 50, 110, 119, 137, 178, 180,  
  195  
  pricing 51  
  reference pricing (RP) 105  
Jacobzone, S. 57, 185  
Jansson, E. 229, 234, 240  
Japan 2, 3, 41, 51  
job security 184  
Johannesson, M. 165  
Juez, P. 228, 233, 240  
Karlsson, G. 166  
Kaufer, E. 57  
Kinked Demand model 111  
Klemperer, P. 26, 33  
Kolassa, E.M. 123  
Korea 41  
Kremer, M. 27, 30, 31, 34  
Kuhn-Tucker 229  
Kwoka, J.E. 62, 83  
laboratory sales representatives 173  
Laffont, J.J. 165  
Langley, P. 166  
Larruga, J. 243  
Las Palmas University, Gran Canaria 17  
Laspeyres price indexes 3, 6  
Latin America 214  
legal protection 24  
Lerner, J. 26, 33  
Levin, R.C. 33  
liberalization 35  
licences 93, 98  
life expectancy 192  
life, quality of 32  
lifestyle drugs 193, 207  
Lillars, L.A. 144  
lipids 193  
Lipsy, R. 166  
Liston, C. 57  
Llor, C. 240  
Lobato, P. 57, 136, 143, 218–19, 231,  
  237, 240  
Lobo, F. 18, 209, 210–30, 240, 243  
  ‘local products’ 82  
  UK 79  
López, Bastida J. 57, 123, 185, 215,  
  223, 231  
López, J.P. 237, 239, 241  
López-Casasnovas, G. 103–22, 144,  
  189–208, 232, 238  
low-income households 132, 141  
Lundberg, L. 144  
Luxembourg 2, 9, 137  
Lyles, A. 143  
Maassen, B.M. 123  
Macho, I. 184  
Majeed, A. 185, 186  
malpractice 180, 183  
Manning, W.G. 144  
marginal costs 117, 148, 160  
Marino, M.A. 227, 233, 239  
markets 85, 217  
  delimitation 85  
  entry 79, 89  
  failures 84  
  penetration 46  
  power 117  
  prices 108  
  rules 168, 169, 171, 172, 184, 542, 4664

- share 66, 68, 74, 119, 121
- marketing 86, 160
- Martín Cruz, Natalia 215, 231, 238
- Martínez, J. 243
- Matutes, C. 26, 33
- McGavock, H. 186
- Medicaid programme 108
- medical
  - budgets 177, 178
  - prescription 59, 60
  - treatment guidelines 18, 146
- Medicare coverage 140
- Medicine Control Agency 79
- medicines 22, 35, 64, 112, 136
  - effective 156
  - for minor ailment 159
  - sales of 212
- Meneu, R. 184
- Mengfbar, F.J. 144
- meningitis B vaccine 24
- menopause symptoms 193
- mental health services 127, 135
- merit goods 85
- Mestre, J. 226, 233, 239
- metabolism 199
- 'me-too' drugs 90, 91
- Mexico 41
- microeconomic techniques 213
- Miguel, J.M. 228, 238
- Ministry of Health and Consumer Affairs 80, 182, 203, 212, 213
- Ministry of Health of the Community of Valencia, Spain 181
- minor ailments, medicine for 159
- modified release preparations 157
- monetary units 145, 162
- monodrugs 228
- monopolies 24, 27, 30, 32, 84, 87, 94, 148
- moral hazard 116, 125, 127–32, 142
- morbidity 136, 192, 214
- mortality, reduction of 32
- Mossialos, E. 57, 92, 137, 144, 185, 209, 215, 223
- multinational companies 92, 93
- multiple applications 26
- Murillo, C. 143
  
- national
  - barriers, abolition 93
  - drug register 221
  - expenditure in Europe 107
  - health authorities 97, 98
  - regulations 76, 79
- National Drug Policy 214
- National Health Service (NHS) 44, 45, 62, 63, 177
- National Health System (Spain) 62, 103, 126, 200
- Navarre 204
- neoprotectionism 221
- Nestre, J. 241
- Netherlands 51, 103, 113, 141, 171, 180
  - reference pricing (RP) 105, 106
- Newhouse, J. 144
- New Zealand 105, 106, 110, 113, 119
- Nonell Torres, R. 59–83, 122, 144, 231, 241
- non-financial incentives 179–82, 184
- non-prescription drugs 38
- North, D. 184
- Northern Ireland 63
- Norway 9, 41, 105, 106, 113, 180
- Noyce, P.R. 144
- nutrition 129
- Nyman, J.A. 131, 143
  
- O'Donoghue, N. 186
- obesity 193
- Organisation for Economic Co-operation and Development (OECD) 50, 83, 92, 190
  - countries 41, 314
  - figures 2
  - Health Data file 103
  - recommendations 204
- oligopoly 84
- Olmstead, T. 166
- open-source research 99
- optimal prices 44
- orphan drugs 32
- Ortún Rubio, V. 18, 167–84, 243
- overconsumption of drugs 207
- overheads 43
- over-the-counter (OTC) drugs 60, 86, 203, 204
- Oviedo University 18
  
- parallel imports 32, 93
- psychology 199

- patented drugs 38, 113
- patents 22, 24, 27–9, 72, 146
  - abolition of 90
  - drug, product and process 87
  - expiration 38
  - extension 226
  - policy 18, 146
  - protection 17, 21, 32, 52
  - rights 97
  - short-duration 26
  - system 29, 30, 79, 80, 82, 114
    - unified model 92
    - standardization 33
- patients 18, 48, 86
  - and doctor 106, 114, 116, 134–5
  - convenience 157
  - discrimination between 162, 163
  - failure to follow treatment 136
  - insured 116
  - non-hospital 62
  - welfare 116
- Pauly, M.V. 131, 143
- Pavnik, N. 143
- payment orders 174
- peer reviews 180
- pensioners 126, 137, 222
  - in Spain 201
- personalized treatment 207
- Pharmaceutical Price Regulation Scheme (PPRS) 45, 80, 151
- Pharmaceutical Product Base 63
- pharmaceuticals 85, 103, 131–2, 172, 177, 178
  - cost sharing 125
  - expenditure 1–18, 105, 193–200
    - in Spain 189–208
  - financing 3, 4, 151–56, 161–5
  - industry 21, 22, 31, 202
  - markets 41, 60, 79, 84–99, 120
  - policy 146–7
  - prices 54, 89
  - promotion 183
- Pharmaceuticals Act (Law 13/96), Spain 104
- pharmacies, studies on in Spain 228–30
- PharmacoEconomics* 217
- pharmacological counselling 2, 11
- physicians 168, 169, 181
- physiological responses 113
- Pinto Prades, J.L. 17, 243
- Pla, F. 241
- Plant, A. 24, 33
- Poland 105
- political problem of discrimination 162, 163
- Pompeu Fabra University 16, 17, 18, 212
- population 29, 214
  - ageing 191
  - culture 168, 174
  - groups needing most medicines 142
  - in Spain 190
- Portugal 2, 3, 9, 51, 103, 137
- poverty 163
- prescriber 11 37
  - behaviour 18, 168, 173, 180
  - and consumers 89
  - incentive policies 167–84, 174–83
    - in the USA 174
- prescription 18, 85, 167, 180, 217
  - concentration 69
  - costs 179
  - drugs 14, 35, 62, 86, 105, 135, 139, 204
  - guidelines 11
  - monitoring 170, 171, 172
  - related costs 116
  - in Spain 198
  - standardization of 141
- presentation of drug 113
- preventive services 129
- price
  - caps for new drugs 223
  - competition 17, 84–99, 104, 121, 229
  - control 38, 39, 52, 142, 171, 194, 225
  - deregulation 51–6
  - fixing 35, 41
  - freedom 79, 160
  - freezes 41, 92
  - increase 119
  - intervention 15, 35, 92, 215, 217, 224–5
  - regulation 14, 47–9, 60, 148–50, 160
    - in the EU 225
    - in Spain 81
  - regulation system 35, 56, 43–4, 100–12
    - international experience 39–43
    - justification of 36–9

- price-cap regulation (PCR) 35, 44,  
47–9, 110, 225, 229
- prices 43–4, 117, 118, 119, 141, 194
- pricing 31, 41, 148, 149, 160–61
- primary care groups (PCGs) 177, 178,  
184
- Spain 135
- private health care 31, 32, 116, 128,  
173, 190
- prizes for innovation 32
- products 37, 49, 84, 86, 87, 205
- profit control systems 41
- profits of pharmaceutical companies 43,  
92, 94
- prognosis 167
- property rights 21
- Protamine 64
- protection mechanisms 14, 22, 23, 80
- period and scope 25–6
- psychotropic drugs 127
- public
- expenditure 170, 196, 205, 222
  - on pharmaceuticals, Spain 222
  - financing 59, 110–12, 115, 160, 189,  
217
  - funding of R&D 99
  - health systems 65, 79, 81, 141, 174,  
190
  - insurance systems 124, 139
  - intervention 84, 85
  - production 32
- Puig-Junoy, J. 35–56, 103–22, 143, 144,  
195, 209, 225, 233, 241
- Puigventós, L. 144
- purchasing power 98
- QALY 7, 145, 158–65
- quality of product 90
- R&D 27, 36, 39, 41–46, 87, 90–91, 115,  
161, 208, 217
- costs 59, 98, 117
  - expenses 145, 148, 150, 160,
- Rafferty, T. 186
- Ramsey Criterion 44
- Ramsey, Frank 94, 100
- Ramsey prices 47, 94–8 149
- Rand Corporation 138, 140
- Rand Experiment 131
- random trials 138
- Rapp, R.T. 57
- rate of return regulation (RORR) 44–7,  
80
- rationality 135–6
- Reekie, W. 91, 99
- reference inflation index 49
- reference pricing (RP) 16, 17, 92,  
103–22, 151, 161, 194, 222
- justification for 115–18
  - objective and background 105–108
  - systems 113
- regional medical association 179
- registration 16, 215
- and economic evaluation 157–65
  - and marketing authorization 89
  - of medicines 104
  - and pharmaceuticals 35, 36, 59–83,  
147–57
  - theory 215–16
  - in the UK 79
- regulatory process 157, 158
- reimbursement 18, 35, 92, 103–22, 146
- Reol, J.M. 241
- research 26, 27, 29, 148, 173, 211
- and technological development  
220–21
- Research Centre for Economics and  
Health 212
- resource allocation 47, 84
- respiratory system 64, 199
- retail market 80, 108, 204
- Revilla, R. 225, 233, 238
- Rey, J. 185
- Rice, N. 185
- rights of patent holder 26
- Rincón, A. 241
- risk 25, 126, 138, 147, 177, 179
- Roberts, S.J. 185
- Rodríguez, A. 241
- Rodríguez, B. 243
- Rogerson, W.P. 31, 32, 34
- Rovira Forns, J. 16, 84–99, 215–16,  
219, 231–32, 238–41, 244
- Rowgowski, J. 144
- Sacristán, J.A. 244
- Sáenz, M.T. 241
- safety of products 37, 157, 165
- sales

- sales (*cont.*):  
  information 30  
  representatives 173–4, 180
- Samuelson, P. 24, 33
- Santa Creu i Sant Pau Hospital 17
- Santaló, M. 241
- Santoro, F.M. 220, 232, 239
- Sargent, J.A. 83
- savings 119, 179
- Scherer, F.M. 52, 57, 58, 117, 123, 215, 226
- Schmeinck, W. 185
- Schweitzer, S. 99
- Scotland 63
- Segouin, C. 186
- Segú, L. 241
- Segura, M. 214, 226, 233, 238
- self-prescribed drugs 134, 135
- sensory organs 199
- Shavell, S. 29, 30, 34
- Shepherd, W.G. 60, 83
- side effects 114, 147, 158, 159, 167
- Simon, H. 100
- Single European market 93, 214, 221
- skin care 199
- Slovenia, reference pricing in 105
- Slutsky equation 131
- social insurance system 126, 206
- Social Security 42–3, 189, 219
- social welfare 39, 115, 168, 173, 183, 229
- solidarity 98
- Soumerai, S.B. 143, 180, 181, 186
- South Africa 91, 180
- Spain 65–76, 173, 178  
  drug consumption 195, 198, 218  
  drug prices, intervention 121  
  price regulation 51, 81  
  public health system 103, 136  
  reference pricing (RP) policy 120, 226
- Spanish General Law on Health 190, 207
- Spanish Law on Pharmaceuticals 214
- Spanish Ministry of Health and Consumer Affairs 105
- Spanish Ministry of Science and Technology 208
- Spanish Social Security 203  
  prescriptions 199
- specialization 97, 178, 179, 212
- spending 50–51, 141  
  on advertising 88
- sport 129
- Spulber, D.F. 165
- state regulation 168–71, 221
- statins 191
- statistical techniques 213
- Stuart, B. 140, 144
- submarkets 35
- subsidies 127, 156, 163
- substances, new 72
- substitute drugs 31, 85, 110
- sunk costs 149, 160
- supply factors 87–9
- supply side 117, 169, 202–204
- Sweden 10, 114, 137, 195  
  equivalence 113,  
  reference pricing in 105, 106
- Switzerland 1, 10, 41, 51
- tablets 63
- Tamborero, G. 186
- tariff barriers 93
- Tarragona, Spain 204
- taxes 31, 88, 126, 190, 191, 192
- tax-raising 222
- teamwork 184
- technological innovation 99, 208
- technology 48, 141, 192, 207, 214
- telecommunications 208
- temporary residence 178
- tenders, sealed-envelope 31
- therapeutic  
  and generic competition 65–76  
  equivalence 113, 151  
  groups 38, 137, 138  
  health provision 191  
  markets 64  
  substitutes 16, 38, 49, 59, 228  
  value 163, 201, 208
- Therapeutic Drug Classification (Spain) 63
- Thomas, L.G. 79, 83
- Towse, A. 83
- trade 221  
  between countries 32  
  names 86, 87  
  parallel 214, 217  
  trade names, *see* brand names

- trade-related aspects of Intellectual Property (TRIPS) 28, 29
- trading capital 41
- training 18  
and research 184
- transaction costs 39, 43
- treatment 18, 64, 135, 181, 182  
alternative 41  
effectiveness 135  
personalized 192  
subsidizing of 156
- Trillo, J.L. 186, 244
- Turkey 10
- two-tariff pricing 150
- United Kingdom 137, 178, 180, 197–8  
free pricing 151  
prices 51
- United Nations Industrial Development Organization 213
- unification of prices 92
- unit prices 50, 106
- units per package 63, 64
- universal remedies 39
- Urbanos, R.M. 241
- urinogenital 199
- Uruguay Round 28, 215
- US Dept of Health and Human Services 166
- US Medicare programme 140
- USA 35, 41, 91, 180  
free pricing 151  
private insurance 140, 190
- utility functions 164
- vaccines 25
- Valencia, Spain 181
- Valladolid University 227
- Vázquez, J.L. 232, 238
- Viagra 193
- Villalba, F. 238
- Villanueva, P. 185
- Viscusi, W.K. 165
- Vitalba, F. 234
- vitamins 136
- voluntary insurance 126
- Wales 63
- Walley, T. 166
- Waterson, M. 230, 234
- Wazana, A. 185
- wealth 92, 98
- Weinstein, M.C. 166
- welfare 26, 44, 84–99, 125, 191  
economics 110  
function 167  
loss 14, 23, 27, 30, 31, 84, 127, 129, 131  
of patients 208
- World Health Organization 98, 209, 214, 227,  
Action Programme on Essential Drugs 214
- wholesale distributors 80
- Wiggins, S.M. 52, 58
- Woodfield, A. 122
- working conditions 184
- workplace 184
- world production 29
- World Trade Organization 28–9, 33, 92, 99
- worldwide products UK 79
- Ypersele 29, 30
- Zammit-Lucia, J. 122
- Zara, C. 185
- zero risk 157
- Zweifel, P. 138, 143, 144

